Animal model of anxiety and depression
AssigneeThe University of Mississippi
InventorKenneth J. Sufka
Life of this patent
Estimating the term…
Abstract
This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic/antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects. This new animal model is especially useful in detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode.
Claims6
A method to screen for treatment-resistant antidepressant drugs, wherein at least one drug is screened for antidepressant activity in a plurality of fowl chicks with stress vulnerability comprising:
- a) providing said plurality of fowl chicks with stress vulnerability, wherein a first portion of said plurality of fowl chicks with stress vulnerability receives said at least one drug and a second portion of said plurality of fowl chicks with stress vulnerability do not receive said at least one drug, and wherein said plurality of fowl chicks with stress vulnerability is insensitive to at least two classes of antidepressants selected from tricyclic antidepressants, selective norepinephrine reuptake inhibitors (SNRI), and selective serotonin reuptake inhibitors (SSRI), and wherein said plurality of fowl chicks with stress vulnerability is sensitive to the N-Methyl-D-aspartate (NMDA) receptor antagonist ketamine;
- b) audibly separating at least one fowl chick with stress vulnerability individually from said first portion and second portion of fowl chicks with stress vulnerability without noxious stimulus;
- c) recording distress vocalizations of said at least one individually separated fowl chick with stress vulnerability at a recording time period;
- d) converting distress vocalizations of said at least one individually separated fowl chick with stress vulnerability over time into a DVocs rate;
- and
- e) determining the effectiveness of said at least one drug by evaluating the DVocs rate of said at least one individually separated fowl chick with stress vulnerability from said first portion of fowl chicks with stress vulnerability and from said second portion of fowl chicks with stress vulnerability at said recording time period;
- wherein said plurality of fowl chicks with stress vulnerability comprises Black Australorps.
Dependencies are inferred from the claim text.